Sonographically guided radiofrequency ablation with and without a superficial saline injection to prevent skin burns in a rabbit model

Radiofrequency ablation of recurrent thyroid cancers: anatomy-based management

Although differentiated thyroid cancer has an excellent prognosis and low mortality, its recurrence rate has been reported to be very high. While surgery is recommended as the standard treatment for recurrent thyroid cancer, reoperation may increase the incidence of complications due to fibrosis and anatomical distortion. In patients with high surgical risk or those who refuse repeated surgery, ultrasonography-guided ablation techniques including radiofrequency ablation, ethanol ablation, and laser ablation are suggested as alternative treatments. In this manuscript, we introduce an anatomy-based management concept for radiofrequency ablation for recurrent thyroid cancer, and present a review of the relevant literature, including indications, basic techniques, clinical outcomes, and complications.

Ethanol and thermal ablation for malignant thyroid tumours

Papillary thyroid carcinoma (PTC) is the most common subtype of thyroid malignancy and has a good prognosis and low mortality rate. Surgery is the standard treatment for patients with primary and recurrent thyroid cancer. Although patients with PTC usually exhibit excellent treatment outcome, the incidence of recurrence in the neck ranges from 20% to 59%. When a patient with thyroid cancer is contraindicated for surgery, ultrasound (US)-guided ablation techniques, including ethanol ablation (EA) and thermal ablations, are suggested alternatives. In this review, we evaluated the indications, devices, techniques, clinical outcomes, and complications associated with US-guided EA and thermal ablations based on available scientific evidence and expert opinions regarding the use of ablation for primary and recurrent thyroid cancers.

[Establishment of Orthotopic Xuanwei lung cancer SCID mouse model and analysis of biological properties]

背景与目的

宣威女性肺癌发病率居全国首位，亟待深入探讨其发病机制。本研究拟建立SCID小鼠原位宣威肺癌模型，为该病的深入研究提供实验平台。

方法

将宣威肺癌细胞XWLC-05分别以高低剂量接种于SCID小鼠肺原位，并与皮下移植瘤比较，观察成瘤率、成瘤特性、自发性转移及生存情况。

结果

原位移植高低剂量组的成瘤率分别为81%和83%，其中高剂量组接种后13天小鼠出现恶液质、对侧肺及胸腔的广泛粘连，无远处转移；低剂量组接种后25天小鼠出现恶液质及远处转移。皮下移植高低剂量组成瘤率分别为100%及94.5%，无远处转移。原位移植组组内及皮下与原位移植组组间的转移率存在统计学差异（P < 0.05）。两组组内和组间的生存率比较有统计学差异（P < 0.001）。

结论

成功建立了宣威肺癌的SCID小鼠原位动物模型，为该病的深入研究奠定了实验基础。